Umoja is developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $363M
Founded date: 2019
Investors 6
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | DCVC | dcvc.com/ |
| - | Myeloma In... | myelomainv... |
| - | WRF Capita... | wrfseattle... |
| - | Realm Capi... | realmcapit... |
| - | MPM BioImp... | mpmbioimpa... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 20.01.2025 | Series C | $100M | - |
| 21.06.2021 | Series B | $210M | - |
| 18.11.2020 | Series A | $53M | - |
Mentions in press and media 23
| Date | Title | Description |
| 05.11.2025 | Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies | CAMBRIDGE, Mass., Nov. 5, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I™), today announced an evaluation and license agreement with Umoja Biopharma ... |
| 20.01.2025 | Umoja Biopharma's $100 Million Leap: A New Era for In Vivo CAR T Cell Therapies | Umoja Biopharma is on the rise. The Seattle-based company has just secured $100 million in Series C financing. This is not just a number; it’s a statement. It signals a bold step forward in the world of biotechnology. The funding round was ... |
| 20.01.2025 | Umoja Biopharma Raises $100M in Series C Financing | Umoja Biopharma, a Seattle, WA-based clinical-stage company which specializes in vivo cell therapies, raised $100M Series C financing. The round was led by Double Point Ventures and DCVC Bio, with participation from new and existing investo... |
| 14.01.2025 | Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical Milestones | Series C financing co-led by Double Point Ventures and DCVC Bio Proceeds to support the clinical development of VivoVec™ derived in vivo CAR T cells SEATTLE, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stag... |
| 14.09.2024 | Nona Biosciences and Umoja Biopharma: A New Era in CAR-T Cell Therapy | In the ever-evolving landscape of biotechnology, collaboration often serves as the catalyst for innovation. Nona Biosciences and Umoja Biopharma have recently forged a partnership that promises to redefine the boundaries of CAR-T cell thera... |
| 13.09.2024 | Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies | CAMBRIDGE, Mass., Sept. 13, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), announced today that it has entered into a multi-target antibody discovery... |
| 12.09.2024 | Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies | CAMBRIDGE, Mass., Sept. 12, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), announced today that it has entered into a multi-target antibody discovery... |
| 04.01.2024 | IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies | SAN JOSE, Calif., SHANGHAI and NANJING, China, Jan. 4, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies a... |
| 21.11.2022 | Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies | Collaboration will bring together Umoja's iCIL platform and IASO's chimeric antigen receptors to create the next generation of broadly accessible, readily available cell therapies in indications that are significantly underserved by today's... |
| 27.07.2021 | Umoja Biopharma Expands Management Team with Key Hires in Research and Business Development |
Show more